Brazil’s richest and most populous state, Sao Paulo, warned its ability to care for seriously ill Covid-19 patients was on the verge of collapse as it ran perilously low on key drugs, according to a letter to the federal government seen by the Folha de Sao Paulo newspaper.
Eli Lilly said on April 12 the company had a revised agreement with the U.S. government for the Covid-19 antibody drug bamlanivimab, which will now be sold in combination with another therapy.
Japanese health authorities are concerned that variants of the coronavirus are driving a nascent fourth wave in the pandemic with just 109 days remaining until the Tokyo Olympics.
India reported a record rise in Covid-19 infections on April 5, becoming the second country after the United States to post more than 100,000 new cases in a day, as politicians stage massive election rallies raising fears of further spreading the virus.
Pfizer Inc. and BioNTech said on April 1 their Covid-19 vaccine is around 91 percent effective at preventing the disease, citing updated trial data that included participants inoculated for up to six months.
Pfizer and BioNTech on March 31 announced data from a Phase III study which showed 100 percent efficacy and robust antibody responses in patients ages 12-15 years old who received the BNT162b2 vaccine.
A critical component of the immune system known as T cells that respond to fight infection from the original version of the novel coronavirus appear to also protect against three of the most concerning new virus variants, according to a U.S. laboratory study released on March 30.
One dose of Pfizer COVID-19 vaccine offers an immune response similar to that generated by infection and could also offer protection from variants to people who have previously had the virus, a British study said on March 26.
With the increase of multiple variants of Covid-19 across the United States, the U.S. Food and Drug Administration will limit the use of monoclonal antibody treatments developed by Regeneron and Eli Lilly due to concerns the medications are not effective against these new strains.
Belgium-based ExeVir announced a $50 million Series A to take the 9-month-old startup’s lead antibody compound XVR011 into a global Phase Ib/II clinical study soon, representing the first in-human trials using a unique, llama-derived antibody.